S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in
OTCMKTS:PPMD

Protide Pharmaceuticals Stock Forecast, Price & News

$0.09
0.00 (0.00 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.09
Now: $0.09
$0.09
50-Day Range
$0.09
MA: $0.16
$0.28
52-Week Range
$0.09
Now: $0.09
$0.28
VolumeN/A
Average Volume8,250 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta1.43
Protide Pharmaceuticals, Inc. discovers, develops, and commercializes technologies and processes in the areas of clinical cell therapy, regenerative medicine, transfusion medicine, cell engineering, and transplantation in the United States and internationally. It offers serum reducers, cell culture and processing products, stem cell cryopreservatives, and stem cell and regenerative research products. The company is based in Lake Zurich, Illinois.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PPMD
CUSIPN/A
CIKN/A
Phone847-726-3100
Employees3
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

1820th out of 1,956 stocks

Biological Products, Except Diagnostic Industry

175th out of 177 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$0.09
0.00 (0.00 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PPMD News and Ratings via Email

Sign-up to receive the latest news and ratings for PPMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Protide Pharmaceuticals (OTCMKTS:PPMD) Frequently Asked Questions

What stocks does MarketBeat like better than Protide Pharmaceuticals?

Wall Street analysts have given Protide Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Protide Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Protide Pharmaceuticals' key executives?

Protide Pharmaceuticals' management team includes the following people:
  • Mr. Milo R. Polovina, Chairman, CEO, Pres, Principal Financial Officer, Sec. and Treasurer (Age 65)

Who are some of Protide Pharmaceuticals' key competitors?

What is Protide Pharmaceuticals' stock symbol?

Protide Pharmaceuticals trades on the OTCMKTS under the ticker symbol "PPMD."

How do I buy shares of Protide Pharmaceuticals?

Shares of PPMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Protide Pharmaceuticals' stock price today?

One share of PPMD stock can currently be purchased for approximately $0.09.

How many employees does Protide Pharmaceuticals have?

Protide Pharmaceuticals employs 3 workers across the globe.

What is Protide Pharmaceuticals' official website?

The official website for Protide Pharmaceuticals is www.protidepharma.com.

Where are Protide Pharmaceuticals' headquarters?

Protide Pharmaceuticals is headquartered at 1311 Helmo Avenue, Saint Paul MN, .

How can I contact Protide Pharmaceuticals?

Protide Pharmaceuticals' mailing address is 1311 Helmo Avenue, Saint Paul MN, . The company can be reached via phone at 847-726-3100.


This page was last updated on 2/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.